Understanding cervical cancer treatment and characteristics in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the characteristics and treatment patterns of patients with locally advanced or recurrent/metastatic cervical cancer in Italy. By reviewing medical records from oncologic clinics between January 2018 and December 2021, the study will capture data on patient demographics, disease characteristics, and treatment approaches. The study will categorize patients based on risk levels and assess differences in treatment strategies. This retrospective analysis will provide valuable insights into the management of cervical cancer in the specified population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \& Privacy Form (ICF)
* Age ≥18 years
* Diagnosis of a cervical cancer
* Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease
* Any treatment received between January 2018 and December 2021 for advanced disease

Exclusion Criteria:

* Patients participating in a pharmacological clinical trial for the treatment of advanced disease
* Patients who participated in a clinical trial
* Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs

Where it's running

• Oncologia Medica Policlinico Sant'Orsola Malpighi
  Bologna, Bologna, Italy Recruiting
• Ginecologia ed Ostetricia A.O. Cannizzaro
  Catania, Catania, Italy Recruiting
• Oncologia Medica 1 IRCCS Ospedale Policlinico San Martino
  Genova, Genova, Italy Recruiting
• Unità di Ginecologia Oncologica Medica IRCCS Ospedale San Raffaele
  Milan, Milano, Italy Recruiting
• Unità Ostetricia, Ginecologia e Ginecologia Oncologica medica Humanitas San Pio X
  Milan, Milano, Italy Recruiting
• Oncologia A.O.U. di Modena - Policlinico
  Modena, Modena, Italy Recruiting

Study contacts

• Study coordinator: Stefania Lopez
• Email: info.studiclinici@opisresearch.com
• Phone: +39 03626331

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PD-1 versus PD-L1 immunotherapy combined with chemotherapy, with or without bevacizumab, for advanced cervical cancer.

  This trial tests whether giving PD-1 or PD-L1 immunotherapy alongside chemotherapy, with or without bevacizumab, helps adults with metastatic, persistent, or recurrent cervical cancer.

  Recruiting Phase 2/3 N.N. Alexandrov National Cancer Centre · Minsk, Lesnoy · NCT07472153

• SHR-A2102 versus investigator's choice chemotherapy for recurrent or metastatic cervical cancer after platinum and PD-(L)1 therapy

  This trial tests whether SHR-A2102 works better than standard chemotherapy for people with recurrent or metastatic cervical cancer whose disease progressed after platinum-based chemotherapy and PD-(L)1 inhibitors.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Guangzhou, Guangdong · NCT07418749

• Comparing neoadjuvant chemoimmunotherapy and concurrent chemoradiotherapy for locally advanced cervical cancer

  This study is testing whether a new treatment combining chemoimmunotherapy and surgery can help people with locally advanced cervical cancer do better than the standard treatment of chemo and radiation.

  Recruiting at 12 sites Phase 2/3 Tongji Hospital · Hefei, Anhui and 11 other locations · NCT06288373

• Neoadjuvant immunochemotherapy for PD-L1-negative locally advanced cervical cancer

  This study is testing a new treatment that combines chemotherapy with a drug called Camrelizumab to see if it can help people with PD-L1-negative locally advanced cervical cancer before surgery.

  Recruiting at 12 sites Phase 2 Tongji Hospital · Hefei, Anhui and 11 other locations · NCT06288360

• Combination treatment for recurrent or metastatic cervical cancer

  This study is testing if adding a new treatment called PRGN-2009 to pembrolizumab can help people with recurrent or metastatic cervical cancer who haven't responded to pembrolizumab alone.

  Recruiting at 3 sites Phase 2 Precigen, Inc · Little Rock, Arkansas and 2 other locations · NCT06157151

• Assessing the effects of radiotherapy on tumors in cervical and pancreatic cancer

  This study is testing how radiotherapy affects tumors in patients with locally advanced cervical and pancreatic cancer by collecting samples and using special imaging before, during, and after treatment.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT05975593

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.